Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2023 Mar 1;24(3):733-736.
doi: 10.31557/APJCP.2023.24.3.733.

Cost of Treatment for Myelofibrosis Patients in Ministry of Health Hospitals in Sarawak, Malaysia

Andy Sing Ong Tang  1 , Tze Shin Leong  1 , Joyce Hong Ling Ong  2 , Adrian Goh  2 , Lee Ping Chew  1
Affiliations
Observational Study

Cost of Treatment for Myelofibrosis Patients in Ministry of Health Hospitals in Sarawak, Malaysia

Andy Sing Ong Tang et al. Asian Pac J Cancer Prev. .

Abstract

Objective: Primary myelofibrosis is a rare type of myeloproliferative neoplasm with an annual incidence rate of 0.47 per 100,000. A retrospective, observational study was conducted to determine the disease evolution and costs of treatment for myelofibrosis (MF) patients managed in 4 Ministry of Health (MOH) hospitals in Sarawak, Malaysia.

Methods: The estimation of treatment cost was a planned analysis of the Real World Evidence (RWE) study which included retrospective chart review of adult MF patients treated in Sarawak General, Sibu, Bintulu and Miri Hospitals. The study was approved by Sarawak General Hospital HRRC and MREC. The current study was conducted to estimate the cost of out-patient visits, hospitalisation, transfusion and medication from the perspective of MOH. Out-patient visits and hospitalisation costs were calculated using current unit costs for full fee-paying charges of MOH hospitals. Transfusion costs were estimated for packed cell and platelet transfusions. Medication costs were calculated using drug prices from IQVIA database for MOH hospital sub-sector in 2021. Unit costs were standardised to index year of 2021.

Result: Data from 63 patients was available for analysis. Mean annual health resource utilisation (HRU) was 6.13 clinic visits, 9.47 days of hospitalisation and 1.61 transfusions per patient per year. Mean HRU cost was RM23,320 (USD5,217) per patient per year, comprised of RM19,122 (USD4,278) in drug costs, RM3,030 (USD678) for hospitalisation, RM799 (USD178) for transfusions and RM368 (USD82) for outpatient cost.

Conclusion: The present analysis suggests that medication and hospitalisation were the main drivers of costs for MF treatment in Sarawak MOH hospitals. This study provides the first RWE estimate of the cost of MF in Malaysia and may provide insight into unmet clinical needs and a guide for further health economic research into the treatment of MF.

Keywords: Healthcare Resource Utilization; Malaysia; Medical Care Costs; Ruxolitinib; primary myelofibrosis.

PubMed Disclaimer

Conflict of interest statement

The authors declare they have no conflict of interests.

References

    1. Bankar A, Zhao H, Iqbal J, et al. Healthcare resource utilization in myeloproliferative neoplasms: a population-based study from Ontario, Canada. Leuk Lymphoma. 2020;61:1908–19. - PubMed
    1. Cools J, DeAngelo DJ, Gotlib J, et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med. 2003;348:1201–14. - PubMed
    1. Copher R, Kee A, Gerds A. Treatment Patterns, Health Care Resource Utilization, and Cost in Patients with Myelofibrosis in the United States. Oncologist. 2022;27:228–35. - PMC - PubMed
    1. Department of Statistics Malaysia. Pocket Stats Negeri Sarawak ST4 2021. 2022. https://cloud.stats.gov.my/index.php/s/IAMCU8OnWfTd2Yj#pdfviewer .
    1. Guglielmelli P, Ghirardi A, Carobbio A, et al. mpact of ruxolitinib on survival of patients with myelofibrosis in the real world: update of the ERNEST Study. Blood Adv. 2022;6:373–5. - PMC - PubMed

Publication types